Medical Marijuana Market (2026 - 2033)

Medical Marijuana Market Summary

The global medical marijuana market size was valued at USD 19.7 billion in 2025 and is expected to grow from USD 23.4 billion in 2026 to USD 67.8 billion in 2033, at a CAGR of 16.4% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 69.5% in 2025. The industry is experiencing growth due to the rising awareness regarding various therapeutic applications of the product, such as pain management, appetite enhancement, and reducing eye pressure. 

Medical marijuana is classified into two types, namely, Cannabis Sativa and Cannabis Indica, which originate from the countries of the western hemisphere and central & south Asian regions, respectively. The growing percentage of countries permitting the usage of medical marijuana in various parts of the world is one of the key factors driving the penetration rate of cannabis in therapeutic applications. With changes in government policies, the demand for medical marijuana is also increasing. Many countries have legalized the usage of medical marijuana, which is the leading way for its cultivation. This will, in turn, lower the imports, leading to revenue generation in the form of taxes.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing number of states legalizing medical marijuana and the growing adoption of cannabis in the healthcare sector and recreational applications are some of the major aspects that are expected to propel the demand for medical marijuana over the coming years. The growing research and development activities are also expected to drive the demand. As per clinical studies, cannabis is highly effective for the treatment of chronic diseases. Owing to the rising prevalence of chronic diseases throughout the globe, the market is expected to see a steep growth in the forecast period.

One of the major challenges faced by the medical marijuana market is that, to date, the FDA has not permitted the marketing usage of cannabis for the treatment of any disease or condition. However, the organization has approved one cannabis-derived drug product: Epidiolex (cannabidiol), and three synthetic cannabis-related drug products, namely Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These permitted drug products are only available with a prescription from a licensed healthcare provider.

Nonetheless, it is anticipated that the consolidation and acquisition of cannabis producers will drive the market expansion. Active research work, proven medical properties, growing legalization, and improvements in intellectual property rights of cannabis are some of the major factors that are expected to fuel the market growth.

Market Dynamics

Analyst Perspective

The medical marijuana market is expected to record sustained long-term growth on account of evolving legalization frameworks and increasing acceptance of cannabis-based therapies. There is a rising demand for alternative pain management and chronic disease treatments. The ongoing clinical research focused on validating the efficacy of medical cannabis across multiple therapeutic applications is likely to play a crucial role in supporting market growth. Engagement in advanced cultivation technologies, pharmaceutical-grade product development, and setting up robust distribution networks will help market players to stay abreast of the competition and have a strong foothold. Key differentiators include product standardization, regulatory compliance, and innovation in cannabinoid formulations tailored to specific medical conditions. As healthcare systems integrate cannabis-based medicines, the market is expected to witness strong investment, innovation, and global expansion.

Product Insights

The oil and tincture dominated the medical marijuana market in 2025 and accounted for the largest revenue share of over 55.6%. The growth is largely attributed to the increasing medicinal use. Clinical studies have shown that non-psychoactive compounds in marijuana, such as CBD, have the property to reduce inflammation and thus have the capability to provide a new treatment for chronic pain. It is also known for its use in treating sleep disorders and anxiety. Moreover, the growing legalization of cannabis throughout the globe is further expected to drive the industry’s growth. In addition, children who consume cannabis derivatives for their treatment are prescribed oils and tinctures, as they cannot use flowers to smoke due to respiratory problems, which can be caused by smoking flowers.

The flower segment is expected to record growth at a slower pace in the coming years. However, the launch of new products is expected to push the market growth of the segment. For instance, in 2025, medical cannabis wellness company Awshad launched a 6500 mg CBD oil for chronic pain, cancer, epilepsy, anxiety, and insomnia, reflecting the increasing of advanced cannabis oil products that are driving segment growth.

Application Insights

By application type, the chronic pain segment held the largest share of around 27.5% in 2025. Studies of various research state that medical cannabis is safe for treating patients with chronic pain and neuropathic pain. The growing number of clinical trials with marijuana to treat neuropathic and chronic pain is one of the key indicators, which highlights the rising usage of cannabis in pain management over the coming few years.

New York’s “New Medical Marijuana Law” states that a patient certified by a healthcare professional to use medical marijuana, possessing a patient identification card registered with the New York State Department of Health, is eligible to use medical marijuana for pain management.

Amyotrophic lateral sclerosis (ALS) is expected to be the fastest-growing application segment during the forecast period. The growing prevalence of amyotrophic lateral sclerosis is one of the factors driving the growth of the segment. Increasing research on cannabinoid-based therapies for neurological disorders is further supporting interest in medical marijuana as a complementary treatment option for ALS patients. The rising focus on improving symptom management and quality of life for individuals with ALS is expected to contribute to the rapid growth of the segment over the forecast period.

Regional Insights

The North America medical marijuana market accounted for the largest revenue share of over 69.5% in 2025. The increasing legalization of cannabis in the U.S. is one of the vital factors contributing to its increased demand. Moreover, in the U.S., 37 states and the District of Columbia have legally permitted the use of cannabis for therapeutic purposes, whereas ten other states have also legalized the usage of cannabis for recreational purposes.

To learn more about this report, Download Free Sample Report

U.S. Medical Marijuana Market Trends

The government of the U.S in May 2025, for the first time in over 50 years, approved new growers of research marijuana. Thus, broadening the capacity to study the drug’s medical value. Furthermore, product launches are also fueling market growth. For instance, in late 2025, Bosnia and Herzegovina officially legalized cannabis for medical use, launching a regulated framework that allows patients to access cannabis-based treatments.

Asia Pacific Medical Marijuana Market Trends

Asia Pacific is anticipated to register the fastest CAGR over the coming years due to growing favorable government initiatives & support. Additionally, a rise in disposable income, increasing social acceptance, and growth in awareness regarding the benefits of the product, along with the increase in the legalization of cannabis, certainly affect the cannabis market. The surge in the popularity of cannabis oil among countries with legalized medical marijuana and the growing percentage of the population suffering from chronic illnesses, such as Parkinson's, Alzheimer's, cancer, neurological disorders, and others, accelerates the growth of the industry.

Key Medical Marijuana Company Insights

The key players are devising various strategic initiatives to expand their business footprint and gain a competitive edge. They are also focusing on strategic initiatives such as mergers & acquisitions, collaborations, partnerships, funding & investments, and innovative product developments & launches to expand their expertise & product portfolio.

Key Medical Marijuana Companies

The following key companies have been profiled for this study on the medical marijuana market.

• Tilray Brands, Inc.

• Aurora Cannabis Inc.

• Canopy Growth Corporation

• Aphria, Inc.

• Maricann Group, Inc.

• Tikun Olam, Ltd.

• MedReleaf. Corp.

• GW Pharmaceuticals plc.

• Cannabis Sativa, Inc.

• Medical Marijuana, Inc.

Recent Developments

• In April 2026, the U.S. Department of Justice (DOJ) and Drug Enforcement Administration (DEA) decided to change the status of state-licensed medical marijuana and FDA-approved cannabis from Schedule I to Schedule III, which represents a very important federal change in medical cannabis policies.

• In April 2026, The Department of Justice of the U.S. set up a streamlined process for the registration process at the DEA for state licensed medical cannabis businesses in 2026. 

Global Medical Marijuana Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global medical marijuana market report on the basis of product type, application, and region:

To learn more about this report, Download Free Sample Report

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Flower

  • Oil & Tinctures

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Cancer

  • Chronic Pain

  • Depression and Anxiety

  • Arthritis

  • Diabetes

  • Glaucoma

  • Migraines

  • Epilepsy

  • Multiple Sclerosis

  • AIDS

  • Amyotrophic Lateral Sclerosis

  • Alzheimer’s Disease

  • Post-Traumatic Stress Disorder (PTSD)

  • Parkinson's Disease

  • Tourettes

  • Others 

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • UAE

    • South Africa